XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS

3 Months Ended

Mar. 31, 2021

(4) STOCK-BASED COMPENSATION PLANS

In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5,000,000 shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon vesting and are not included in outstanding shares until such vesting and issuance occurs.

During the three months ended March 31, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended March 31, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At March 31, 2021, the company had 0.8 million stock options outstanding and 0.6 million exercisable under the following plans:


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	296		296
Equity Compensation Plans not approved by Shareholders	38		25
2017 Stock Option Plan	490		274
Total	824	$	595

During the three months ended March 31, 2021, 65,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan. During the three months ended March 31, 2020, 165,000 shares of restricted stock were granted. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock is typically released quarterly over three years for the Board of Directors and annually or quarterly over four years for management.

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:


	For the Three Months Ended March 31,
	2021		2020
Cost of Revenue	$	15	$	6
Sales and marketing expense		15		29
General, and administrative		78		462
Total stock based compensation expense	$	108	$	497

The Company received proceeds of $27,000 and $0.2 million related to option exercises during the three months ended March 31, 2021 and 2020, respectively.

The Company used the Black-Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the three months ended March 31, 2021 and March 31, 2020.


	For the Three Months
	Ended March 31,
	2021		2020
Expected term (years)	—		6.79
Risk-free interest rate	—	%	1.59	%
Expected volatility	—	%	116.76	%
Expected dividend yield	—	%	—	%

A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Granted	—	$	—
Forfeited	(174)	$	7.65
Exercised	(8)	$	3.12
Outstanding at March 31, 2021	824	$	2.07	5.79	$	10,873

Exercisable at March 31, 2021	595	$	1.73	5.23	$	8,061

A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		65
Forfeited		(66)
Vested		(49)
Granted but not vested at March 31, 2021		218

As of March 31, 2021, the Company had approximately $3.5 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.3 years.